JP2015519313A5 - - Google Patents

Download PDF

Info

Publication number
JP2015519313A5
JP2015519313A5 JP2015507425A JP2015507425A JP2015519313A5 JP 2015519313 A5 JP2015519313 A5 JP 2015519313A5 JP 2015507425 A JP2015507425 A JP 2015507425A JP 2015507425 A JP2015507425 A JP 2015507425A JP 2015519313 A5 JP2015519313 A5 JP 2015519313A5
Authority
JP
Japan
Prior art keywords
seq
pharmaceutical composition
composition according
amino acid
fviii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2015507425A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015519313A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/055107 external-priority patent/WO2013160005A1/en
Publication of JP2015519313A publication Critical patent/JP2015519313A/ja
Publication of JP2015519313A5 publication Critical patent/JP2015519313A5/ja
Withdrawn legal-status Critical Current

Links

JP2015507425A 2012-04-24 2013-03-13 血友病の治療に適する医薬組成物 Withdrawn JP2015519313A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP12165296 2012-04-24
EP12165296.0 2012-04-24
US201261641439P 2012-05-02 2012-05-02
US61/641,439 2012-05-02
EP13150575.2 2013-01-09
EP13150575 2013-01-09
US201361752614P 2013-01-15 2013-01-15
US61/752,614 2013-01-15
PCT/EP2013/055107 WO2013160005A1 (en) 2012-04-24 2013-03-13 Pharmaceutical composition suitable for treatment of haemophilia

Publications (2)

Publication Number Publication Date
JP2015519313A JP2015519313A (ja) 2015-07-09
JP2015519313A5 true JP2015519313A5 (OSRAM) 2016-04-14

Family

ID=49482214

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015507425A Withdrawn JP2015519313A (ja) 2012-04-24 2013-03-13 血友病の治療に適する医薬組成物

Country Status (5)

Country Link
US (2) US20150045303A1 (OSRAM)
EP (1) EP2841091A1 (OSRAM)
JP (1) JP2015519313A (OSRAM)
CN (1) CN104411323A (OSRAM)
WO (1) WO2013160005A1 (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120263701A1 (en) 2009-08-24 2012-10-18 Volker Schellenberger Coagulation factor vii compositions and methods of making and using same
MX369862B (es) 2012-02-15 2019-11-25 Bioverativ Therapeutics Inc Composiciones del factor viii y metodos para hacerlas y usarlas.
NZ628014A (en) 2012-02-15 2016-09-30 Biogen Ma Inc Recombinant factor viii proteins
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
AR101060A1 (es) * 2014-02-12 2016-11-23 Novo Nordisk As Conjugados de fviii
US10251940B2 (en) * 2014-06-06 2019-04-09 Octapharma Ag Preparation comprising factor VIII and Von Willebrand factor peptides
WO2016198521A1 (en) 2015-06-10 2016-12-15 Novo Nordisk A/S Fviii fusion proteins
CA2994547A1 (en) 2015-08-03 2017-02-09 Bioverativ Therapeutics Inc. Factor ix fusion proteins and methods of making and using same
EP3205665A1 (en) * 2016-02-11 2017-08-16 Octapharma AG Method of separating factor viii from blood products
AU2017358865A1 (en) * 2016-11-11 2019-05-09 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
WO2018102743A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
EP3641800B1 (en) 2017-06-22 2023-10-04 CSL Behring Lengnau AG Modulation of fviii immunogenicity by truncated vwf
CN108918235A (zh) * 2018-05-16 2018-11-30 绍兴文理学院 一种肿瘤淋巴结离体标本的固定处理方法
CN108753910A (zh) * 2018-05-16 2018-11-06 浙江思格医疗科技有限公司 一种消化液
SG11202010767SA (en) 2018-05-18 2020-11-27 Bioverativ Therapeutics Inc Methods of treating hemophilia a
CA3115535A1 (en) * 2018-10-23 2020-04-30 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor viii function
CN114072420B (zh) * 2019-07-04 2024-06-11 康诺贝林伦瑙有限公司 用于增加凝血因子viii的体外稳定性的截短的血管性血友病因子(vwf)
EP4013389A1 (en) 2019-08-16 2022-06-22 Octapharma AG Stabilizing buffer for factor viii and vwf

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952198A (en) * 1995-05-04 1999-09-14 Bayer Corporation Production of recombinant Factor VIII in the presence of liposome-like substances of mixed composition
CA2462930C (en) 2001-10-10 2012-07-10 Shawn De Frees Remodeling and glycoconjugation of peptides
AU2007269233B2 (en) * 2006-06-30 2011-06-09 Cnj Holdings, Inc. Method of producing Factor VIII proteins by recombinant methods
EP2486936A1 (en) * 2007-06-13 2012-08-15 CSL Behring GmbH A composition comprising VWF and FVIII preparations for use in treating of bleeding disorders
WO2009108806A1 (en) * 2008-02-27 2009-09-03 Novo Nordisk A/S Conjugated factor viii molecules
CA2740793A1 (en) 2008-11-03 2010-06-03 Haiyan Jiang Method for the treatment of hemophilia
GB0911870D0 (en) * 2009-07-08 2009-08-19 Ucl Business Plc Optimised coding sequence and promoter
JP2013519699A (ja) 2010-02-16 2013-05-30 ノヴォ ノルディスク アー/エス 因子viii融合タンパク質
CN102971006A (zh) * 2010-07-15 2013-03-13 诺沃—诺迪斯克有限公司 稳定的因子viii变体
CN103209992A (zh) 2010-09-15 2013-07-17 诺沃—诺迪斯克有限公司 具有减少的细胞摄取的因子viii变体

Similar Documents

Publication Publication Date Title
JP2015519313A5 (OSRAM)
AR081042A1 (es) Peptidos de la superfamilia de glucagon que presentan actividad del receptor acoplado a proteinas g
NO20092774L (no) HLA-A*1101-begrenset WT1-peptid og farmasoytisk preparat som omfatter dette
CY1114590T1 (el) Εμβολια πεπτιδιου για καρκινους που εκφραζουν ογκο-συναφη αντιγονα
JP2018522563A5 (OSRAM)
JP2010534486A5 (OSRAM)
JP2012522529A5 (OSRAM)
FI3430027T3 (fi) Peptidi käytettäväksi ei-pienisoluisen keuhkosyövän ja pienisoluisen keuhkosyövän hoidossa
RU2014103288A (ru) Слитые полипептиды релаксина и их применение
BR112015032875A2 (pt) derivados de peptídeos do tipo glp-1, e usos dos mesmos
WO2013036778A3 (en) Compstatin analogs with improved pharmacokinetic properties
HRP20240640T1 (hr) Kimerni proteini faktora viii i njihova upotreba
RU2015146614A (ru) Конъюгированная вакцина на основе пептида антигена wt1
UA103882C2 (uk) Композиція пухлино-асоційованих пептидів та відповідна протиракова вакцина
AR064642A1 (es) Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
JP2017523781A5 (OSRAM)
HRP20161305T1 (hr) Liječenje mikrobnih infekcija
RU2016152151A (ru) Препарат, содержащий фактор viii и пептиды фактора фон виллебранда
JP2015532307A5 (OSRAM)
JP2013519698A5 (OSRAM)
RU2017119773A (ru) Пептидные антагонисты пептидных гормонов из семейства кальцитонина (cgrp) и их применение
RU2017126566A (ru) ВСТРЕЧАЮЩИЕСЯ В ПРИРОДЕ миРНК ДЛЯ КОНТРОЛИРОВАНИЯ ЭКСПРЕССИИ ГЕНОВ И ИХ ПРИМЕНЕНИЕ
EP4424366A3 (en) Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf
CN107223133A (zh) 一种可溶的异质二聚t细胞受体及其制法和应用
JP2017501148A5 (OSRAM)